Research study Program year 2023 Source: CMS Open Payments

A Randomized Double Blind Multicenter Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of Subcutaneous Secukinumab in Subjects of Body Weight 90 KG Or Higher With Moderate to Severe Chronic Plaque Type Psoriasis

Research payments

$24,663,765

120 payments

Through program year 2023, $24,663,765 in research payments was reported against A Randomized Double Blind Multicenter Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of Subcutaneous Secukinumab in Subjects of Body Weight 90 KG Or Higher With Moderate to Severe Chronic Plaque Type Psoriasis, across 120 payments, paid by Novartis Pharmaceuticals Corporation.

Paid by: Novartis Pharmaceuticals Corporation
ClinicalTrials.gov: No trial number was reported for this study

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$4,729	2
2022	Research	$15,451	2
2021	Research	$67,907	34
2020	Research	$342,370	40
2019	Research	$24,233,309	42

Breakdown

Who paid Research payments · program years 2019–2023

Novartis Pharmaceuticals Corporation $24,663,765 120 payments

Who received the money Research payments · program years 2019–2023

Psoriasis Treatment Center Of Central New Jersey Organisation paid for research $2,181,990 3 payments
Wright State Physicians INC Organisation paid for research $1,564,922 3 payments
Wentachee Valley Hosptial Department Of Clinical Research Organisation paid for research $1,144,778 3 payments
Mt Sinai St Luke S Roosevelt Organisation paid for research $1,127,000 3 payments
Atlanta Dermatology Vein And Research Center Organisation paid for research $1,064,655 3 payments
Alliance Dermatology Organisation paid for research $1,059,951 1 payment
Carolina Dermatology Of Greenville Organisation paid for research $1,049,280 3 payments
Texas Dermatology Organisation paid for research $1,000,564 2 payments
Palm Beach Research Center Organisation paid for research $863,329 2 payments
Northshore University Healthsystem Organisation paid for research $820,564 2 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.

Cite this record

“A Randomized Double Blind Multicenter Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of Subcutaneous Secukinumab in Subjects of Body Weight 90 KG Or Higher With Moderate to Severe Chronic Plaque Type Psoriasis”, Who Paid My Doc, citing CMS Open Payments, program year 2023. https://www.whopaidmydoc.com/research-studies/a-randomized-double-blind-multicenter-study-assessing-short-16-weeks-and-long-term-efficacy-up-to-1-year-safety-and-tolerability-of-subcutaneous-secukinumab-in-subjects-of-body-weight-90-kg-or-higher-with-moderate-to-severe-chronic-plaque-type-psoriasis-166960543

Figures here may be reproduced with attribution and a link — see for journalists and researchers.